News & Updates

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

16 Jun 2023

Among women with inflammatory bowel disease (IBD), those who have long-term immunomodulator exposure are at increased risk of high-grade cervical intraepithelial neoplasia and cervical cancer (CIN2+), according to a study.

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

16 Jun 2023

Atrial fibrillation patients use same anticoagulant after bleeding event

16 Jun 2023

A recent study has shown that the majority of patients with nonvalvular atrial fibrillation who have had a bleeding event resume anticoagulation therapy usually with the same drug class that they have been using.

Atrial fibrillation patients use same anticoagulant after bleeding event

16 Jun 2023

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023 by

Patients with Alagille syndrome (AS) may benefit from treatment with odevixibat, with the phase III ASSERT study showing that its use results in rapid, sustained, and highly significant improvements in pruritus, sleep quality, as well as decreases in bile acids (BAs). Odevixibat is also well tolerated.

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023

Thiazide plus potassium-sparing diuretics outdoes monotherapy in hypertension

16 Jun 2023

Use of thiazides with potassium-sparing (PS) diuretics results in greater blood pressure (BP)-lowering efficacy, as well as reduces hypokalaemia and hyperglycaemia, compared with thiazides alone, reports a recent study.

Thiazide plus potassium-sparing diuretics outdoes monotherapy in hypertension

16 Jun 2023

Ribociclib plus endocrine therapy: A win for early breast cancer?

16 Jun 2023 by

In the second interim efficacy analysis of the phase III NATALEE trial, a combination regimen comprising the CDK4/6 inhibitor ribociclib and endocrine therapy (ET) demonstrated favourable signals for the adjuvant treatment of stage II/III hormone receptor-positive, HER2-negative (HR+, HER2–) early breast cancer.

Ribociclib plus endocrine therapy: A win for early breast cancer?

16 Jun 2023

Original New Drug Application Approvals by US FDA (01-15 June 2023)

16 Jun 2023

New drug applications approved by US FDA as of 01-15 June 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 June 2023)

16 Jun 2023

Hint of benefit with antifibrotic treatment seen for interstitial lung disease

16 Jun 2023

Antifibrotic treatment appears to put brakes on the decline of lung function, as evidenced by forced vital capacity (FVC) measurements, in patients with interstitial lung disease (ILD) related to connective tissue disease (CTD) or rheumatoid arthritis (RA), according to a study.

Hint of benefit with antifibrotic treatment seen for interstitial lung disease

16 Jun 2023

Telitacicept tied to higher SRI-4 response in SLE patients

16 Jun 2023 by

Among patients with active systemic lupus erythematosus (SLE), treatment with telitacicept significantly increased SLE Responder Index 4 (SRI-4) response rate at week 52 compared with placebo, according to a study presented at EULAR 2023.

Telitacicept tied to higher SRI-4 response in SLE patients

16 Jun 2023

Home BP a better measure of CVD risk than office BP, says study

15 Jun 2023

In middle-aged adults, masked hypertension is associated with several markers of cardiovascular disease (CVD), which suggests that home blood pressure (BP) may be a better predictor of risk, even when the recordings are done with the same measurement device, according to a study.

Home BP a better measure of CVD risk than office BP, says study

15 Jun 2023

Teduglutide effective in children with SBS, but still costly

15 Jun 2023 by

Use of teduglutide is effective against short bowel syndrome (SBS) in paediatric patients, although some children need a longer duration of treatment to achieve enteral autonomy, according to a Spain study presented at ESPGHAN 2023. Predictive factors of response to treatment have not been identified.

Teduglutide effective in children with SBS, but still costly

15 Jun 2023

News & Updates

Filter by Specialty:

Specialty:

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

Atrial fibrillation patients use same anticoagulant after bleeding event

Atrial fibrillation patients use same anticoagulant after bleeding event

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

Thiazide plus potassium-sparing diuretics outdoes monotherapy in hypertension

Thiazide plus potassium-sparing diuretics outdoes monotherapy in hypertension

Ribociclib plus endocrine therapy: A win for early breast cancer?

Ribociclib plus endocrine therapy: A win for early breast cancer?

Original New Drug Application Approvals by US FDA (01-15 June 2023)

Original New Drug Application Approvals by US FDA (01-15 June 2023)

Hint of benefit with antifibrotic treatment seen for interstitial lung disease

Hint of benefit with antifibrotic treatment seen for interstitial lung disease

Telitacicept tied to higher SRI-4 response in SLE patients

Telitacicept tied to higher SRI-4 response in SLE patients

Home BP a better measure of CVD risk than office BP, says study

Home BP a better measure of CVD risk than office BP, says study

Teduglutide effective in children with SBS, but still costly

Teduglutide effective in children with SBS, but still costly